Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 4/20 | 0.38 |
| ▸ | JAK1 | P23458 | 4/20 | 0.38 |
| ▸ | TYK2 | P29597 | 3/20 | 0.38 |
| ▸ | JAK3 | P52333 | 3/20 | 0.38 |
| ▸ | CCR5 | P51681 | 6/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | XBP1 | P17861 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4111147 | 0.99 | CYP3A4 (0.39) | CYP3A4JAK2JAK1TYK2JAK3 | |
| SCHEMBL13800335 | 0.98 | CYP3A4 (0.39) | CYP3A4JAK2JAK1TYK2JAK3 | |
| Hydrochloric Acid SCHEMBL7218578 | 0.97 | CYP3A4 (0.39) | CYP3A4JAK2JAK1TYK2JAK3 | |
| SCHEMBL13813617 | 0.95 | CYP3A4 (0.38) | CYP3A4JAK2JAK1TYK2JAK3 | |
| SCHEMBL13800898 | 0.95 | DRD2 (0.40) | CYP3A4JAK2JAK1TYK2JAK3 | |
| SCHEMBL13800360 | 0.94 | JAK2 (0.36) | CYP3A4JAK2JAK1TYK2JAK3 | |
| SCHEMBL13800585 | 0.94 | JAK2 (0.39) | CYP3A4JAK2JAK1TYK2JAK3 | |
| Hydrochloric Acid SCHEMBL4132310 | 0.94 | DRD2 (0.40) | CYP3A4JAK2JAK1CCR5CHRM2 | |
| Hydrochloric Acid SCHEMBL7217743 | 0.94 | JAK2 (0.36) | CYP3A4JAK2JAK1TYK2JAK3 | |
| SCHEMBL13800663 | 0.94 | JAK2 (0.38) | CYP3A4JAK2JAK1TYK2JAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100016358-A1 | GAMMA-GLOBIN INDUCER | KOWA CO., LTD. (JP) | 2010-01-21 | — | — | US | claimed |
| EP-2080759-A1 | GAMA-GLOBIN INDUCER | Kowa Company, Ltd. (JP) | 2009-07-22 | — | — | EP | claimed |
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | KOWA CO., LTD. (JP) | 2009-06-04 | — | — | US | claimed |
| US-20070043078-A1 | Angiogenesis inhibitor | KOWA CO., LTD. (JP) | 2007-02-22 | — | — | US | claimed |
| EP-1674100-A1 | ANGIOGENESIS INHIBITOR | Kowa Co., Ltd. (JP) | 2006-06-28 | — | — | EP | claimed |
| US-20060040986-A1 | Erythropoietin production accelerator | KOWA CO., LTD. (JP) | 2006-02-23 | — | — | US | claimed |
| EP-1568691-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | Kowa Co., Ltd. (JP) | 2005-08-31 | — | — | EP | claimed |
| US-20050176764-A1 | Medicine for treating cancer | KOWA CO., LTD (JP) | 2005-08-11 | — | — | US | claimed |
| EP-1494670-A1 | MEDICINE FOR TREATING CANCER | Kowa Co., Ltd. (JP) | 2005-01-12 | — | — | EP | claimed |
| WO-2003086397-A1 | MEDICINE FOR TREATING CANCER | KOWA CO., LTD. (JP) | 2003-10-23 | — | — | WO | claimed |
| EP-2678339-B1 | Methods and compositions for treating beta-thalassemia and sickle cell disease | ACADEMIA SINICA (TW) | 2016-07-13 | — | — | EP | disclosed |
| US-20100016358-A1 | GAMMA-GLOBIN INDUCER | KOWA CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| US-20100016358-A1 | GAMMA-GLOBIN INDUCER | KOWA CO., LTD. (JP) | 2010-01-21 | — | — | US | disclosed |
| EP-2080759-A1 | GAMA-GLOBIN INDUCER | Kowa Company, Ltd. (JP) | 2009-07-22 | — | — | EP | disclosed |
| EP-2080759-A1 | GAMA-GLOBIN INDUCER | Kowa Company, Ltd. (JP) | 2009-07-22 | — | — | EP | disclosed |
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | KOWA CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | KOWA CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
| JP-2007063163-A | COMPOSITION CONTAINING SPARINGLY WATER-SOLUBLE PIPERIDINE DERIVATIVE OR ITS SALT AND METHOD FOR PRODUCING THE SAME | KOWA CO | 2007-03-15 | — | — | JP | disclosed |
| US-20070043078-A1 | Angiogenesis inhibitor | KOWA CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1674100-A1 | ANGIOGENESIS INHIBITOR | Kowa Co., Ltd. (JP) | 2006-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176764-A1 | Medicine for treating cancer | HDAC4, HDAC3, NR4A3 | CYP3A4 1615/4885JAK2 2487/4885JAK1 4594/4885 |
| US-20060040986-A1 | Erythropoietin production accelerator | EPOR, GHRHR, ARL1 | CYP3A4 3032/4885JAK2 153/4885JAK1 1998/4885 |
| US-20070043078-A1 | Angiogenesis inhibitor | FLT4, FLT1, KDR | CYP3A4 1362/4885JAK2 653/4885JAK1 1622/4885 |
| US-20090143430-A1 | ERYTHROPOIETIN PRODUCTION ACCELERATOR | EPOR, GHRHR, ARL1 | CYP3A4 3032/4885JAK2 153/4885JAK1 1998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.